SAB Biotherapeutics, Inc.
SABS
$3.72
$0.082.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 114.70K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 114.70K | -- |
| Cost of Revenue | 489.90K | -6.98M | 7.66M | 7.65M | 482.40K |
| Gross Profit | -489.90K | 6.98M | -7.66M | -7.54M | -482.40K |
| SG&A Expenses | 3.71M | 2.74M | 3.11M | 2.47M | 3.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.68M | 9.73M | 10.77M | 10.12M | 11.31M |
| Operating Income | -12.68M | -9.73M | -10.77M | -10.01M | -11.31M |
| Income Before Tax | 45.45M | -10.11M | -5.20M | -11.39M | -10.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.45M | -10.11M | -5.20M | -11.39M | -10.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.45M | -10.11M | -5.20M | -11.39M | -10.35M |
| EBIT | -12.68M | -9.73M | -10.77M | -10.01M | -11.31M |
| EBITDA | -11.91M | -8.96M | -9.99M | -9.22M | -10.34M |
| EPS Basic | 0.50 | 0.75 | -0.56 | -1.23 | -1.12 |
| Normalized Basic EPS | 2.66 | -0.68 | -0.35 | -0.77 | -0.70 |
| EPS Diluted | -0.21 | 0.75 | -0.56 | -1.23 | -1.12 |
| Normalized Diluted EPS | 0.36 | -0.68 | -0.35 | -0.77 | -0.70 |
| Average Basic Shares Outstanding | 10.66M | 9.30M | 9.29M | 9.29M | 9.26M |
| Average Diluted Shares Outstanding | 77.86M | 9.30M | 9.29M | 9.29M | 9.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |